Modification of Aldosterone Secretion and Electrolyte Excretion in Man by a Chemical Inhibitor of 18-Oxidation

Abstract

Studies with 3-(1,2,3,4-tetrahydro-1-oxo-2-naphthyl)-pyridine (SU-9055) show it to be an effective inhibitor of aldosterone secretion when administered to human subjects in a dosage of 4.8 g/day. Inhibition of aldosterone secretion is accompanied by an increase in sodium excretion. SU-9055 has no natriuretic effect in the absence of the adrenal glands and does not inhibit the renal action of aldosterone-like steroids. Inasmuch as SU-9055 inhibits aldosterone secretion despite increasing secretion of its 18-deoxy precursor, corticosterone, it is inferred that SU-9055 acts as an inhibitor of 18-oxidation.